Impact of diabetes, obesity, and dyslipidemia on the risk of hepatocellular carcinoma in patients with chronic liver diseases
- PMID: 35934813
- PMCID: PMC9597232
- DOI: 10.3350/cmh.2021.0383
Impact of diabetes, obesity, and dyslipidemia on the risk of hepatocellular carcinoma in patients with chronic liver diseases
Abstract
Despite the increasing prevalence of metabolic disorders, the potential effects of metabolic factors on hepatocellular carcinoma (HCC) development in individuals with chronic liver diseases (CLDs) are not well understood. For a metabolic factor to be identified as a risk factor for HCC in patients with CLDs, such as hepatitis B virus (HBV) and hepatitis C virus (HCV) infection, there should be a strong synergistic interaction between the carcinogenic mechanisms of the metabolic factor and the CLD itself. This review aims to comprehensively summarize the published data on the relationship between metabolic factors such as diabetes mellitus (DM), obesity, and blood lipids and the risk of HCC in patients with CLDs. DM consistently increases the risk of HCC in patients with CLD. When associated with DM, the risk of HCC seems to be highest in HCV and non-alcoholic fatty liver disease (NAFLD), followed by alcoholic liver disease (ALD) and HBV. Obesity may increase the risk of HCC. Among CLDs, the evidence is relatively consistent and clear for ALD, while clear evidence is limited in other CLDs including HBV, HCV, and NAFLD. Total cholesterol, potentially low-density lipoprotein cholesterol and triglyceride, seems to have strong inverse associations with HCC in individuals with CLDs. Despite evidence from observational studies, statins had no effect in preventing HCC in randomized controlled trials. Whether statins have a preventive effect against HCC is unclear. A better understanding and management of metabolic factors may be beneficial to reduce the risk of HCC in patients with CLDs.
Keywords: Diabetes mellitus; Dyslipidemias; Hepatocellular carcinoma; Obesity.
Conflict of interest statement
The authors have no conflicts to disclose.
Similar articles
-
Risk factors for non-alcoholic fatty liver disease are common in patients with non-B non-C hepatocellular carcinoma in India.Indian J Gastroenterol. 2017 Sep;36(5):373-379. doi: 10.1007/s12664-017-0785-x. Epub 2017 Oct 4. Indian J Gastroenterol. 2017. PMID: 28975595
-
Non-alcoholic fatty liver disease is associated with greater risk of 30-day hospital readmission in the United States (U.S.).Ann Hepatol. 2023 Jul-Aug;28(4):101108. doi: 10.1016/j.aohep.2023.101108. Epub 2023 Apr 23. Ann Hepatol. 2023. PMID: 37088421
-
Associations between type 2 diabetes mellitus and chronic liver diseases: evidence from a Mendelian randomization study in Europeans and East Asians.Front Endocrinol (Lausanne). 2024 Mar 1;15:1338465. doi: 10.3389/fendo.2024.1338465. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38495785 Free PMC article.
-
Association of metabolic traits with occurrence of nonalcoholic fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis of longitudinal cohort studies.Saudi J Gastroenterol. 2022 Mar-Apr;28(2):92-100. doi: 10.4103/sjg.sjg_260_21. Saudi J Gastroenterol. 2022. PMID: 34810377 Free PMC article.
-
Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.World J Gastroenterol. 2015 Apr 14;21(14):4103-10. doi: 10.3748/wjg.v21.i14.4103. World J Gastroenterol. 2015. PMID: 25892859 Free PMC article. Review.
Cited by
-
Advances in the Pathogenesis of Metabolic Liver Disease-Related Hepatocellular Carcinoma.J Hepatocell Carcinoma. 2024 Mar 19;11:581-594. doi: 10.2147/JHC.S450460. eCollection 2024. J Hepatocell Carcinoma. 2024. PMID: 38525158 Free PMC article. Review.
-
The Role of Hepatitis Viruses as Drivers of Hepatocancerogenesis.Cancers (Basel). 2024 Apr 15;16(8):1505. doi: 10.3390/cancers16081505. Cancers (Basel). 2024. PMID: 38672587 Free PMC article. Review.
-
Impact of Diabetes Mellitus and Obesity Comorbidities on Survival Outcomes after Hepatocellular Carcinoma Resection: A Multicenter Retrospective Study.Liver Cancer. 2024 Aug 20;14(1):80-91. doi: 10.1159/000540858. eCollection 2025 Mar. Liver Cancer. 2024. PMID: 40144468 Free PMC article.
-
Modulation of glucose metabolism and insulin resistance following hepatitis C virus clearance via direct-acting antivirals.Sci Rep. 2025 Apr 26;15(1):14663. doi: 10.1038/s41598-025-97827-1. Sci Rep. 2025. PMID: 40287451 Free PMC article.
-
Cardiometabolic risk factors in MASLD patients with HCC: the other side of the coin.Front Endocrinol (Lausanne). 2024 May 23;15:1411706. doi: 10.3389/fendo.2024.1411706. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38846491 Free PMC article. Review.
References
-
- Lombardi A, Grimaldi A, Zappavigna S, Misso G, Caraglia M. Hepatocarcinoma: genetic and epigenetic features. Minerva Gastroenterol Dietol. 2018;64:14–27. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical